Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyake, H.
Right arrow Articles by Kamidono, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyake, H.
Right arrow Articles by Kamidono, S.
Clinical Cancer Research Vol. 5, 2824-2829, October 1999
© 1999 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Relative Expression of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 in Mouse Renal Cell Carcinoma Cells Regulates Their Metastatic Potential

Hideaki Miyake1, Isao Hara, Kazuo Gohji, Kazuki Yamanaka, Shoji Hara, Soichi Arakawa, Motowo Nakajima and Sadao Kamidono

Department of Urology, Kobe University School of Medicine, Kobe 650 [H. M., I. H., K. G., K. Y., S. H., S. A., S. K.], and Oncology Research, Novartis Pharma. K.K., Takarazuka 665 [M. N.], Japan

To clarify the significance of the balance between matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) in the progression of renal cell carcinoma, we transfected both the MMP-2 and TIMP-2 genes simultaneously into RenCa, a mouse renal cell carcinoma cell line that does not express detectable levels of either MMP-2 or TIMP-2 mRNAs, and established several clones with various MMP-2:TIMP-2 expression ratios. On the basis of the quantitative evaluation of the MMP-2:TIMP-2 mRNA expression ratio by Northern blot analysis, we selected a clone overexpressing MMP-2 alone (RenCa/M), a clone overexpressing TIMP-2 alone (RenCa/T), and two kinds of clones overexpressing both, i.e., one with a high (RenCa/MTh) and one with a low (RenCa/MTl) MMP-2:TIMP-2 ratio, to compare the tumor cell phenotypes. In an in vitro tumor cell invasion assay, the MMP-2:TIMP-2 ratios of the RenCa sublines were directly correlated with their invasive potential. The invasive abilities of the parental RenCa cells induced by conditioned media from RenCa sublines were also correlated with the MMP-2:TIMP-2 ratios of the sublines. The cell adhesion assay showed the inverse correlation between the MMP-2 expression levels in the sublines and their cell adhesion to several extracellular matrix components. Furthermore, when injected i.v. or into the renal subcapsule in syngeneic mice, RenCa sublines formed metastatic nodules in the lungs, and the number of nodules was correlated with the MMP-2:TIMP-2 ratio of each clone. In contrast, despite the growth-inhibitory effects of TIMP-2 overexpression, MMP-2 overexpression had no effect on either proliferation in vitro of RenCa sublines or on their growth as tumors in vivo. These results suggest that the MMP-2:TIMP-2 expression ratio is a critical factor in the invasion and metastasis of renal cell carcinoma.




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
J. M. Catania, G. Chen, and A. R. Parrish
Role of matrix metalloproteinases in renal pathophysiologies
Am J Physiol Renal Physiol, March 1, 2007; 292(3): F905 - F911.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
T. Okamoto, R. Niu, and S. Yamada
Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary
Mol. Hum. Reprod., October 1, 2003; 9(10): 569 - 575.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Yan and M. A. Moses
A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma
Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190.
[Full Text] [PDF]


Home page
Cancer Res.Home page
T. Etoh, H. Inoue, S. Tanaka, G. F. Barnard, S. Kitano, and M. Mori
Angiopoietin-2 Is Related to Tumor Angiogenesis in Gastric Carcinoma: Possible in Vivo Regulation via Induction of Proteases
Cancer Res., March 1, 2001; 61(5): 2145 - 2153.
[Abstract] [Full Text]


Home page
Mol. Biol. CellHome page
Z. Yang, T. R. Kyriakides, and P. Bornstein
Matricellular Proteins as Modulators of Cell-Matrix Interactions: Adhesive Defect in Thrombospondin 2-null Fibroblasts is a Consequence of Increased Levels of Matrix Metalloproteinase-2
Mol. Biol. Cell, October 1, 2000; 11(10): 3353 - 3364.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.